BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Tempus, AstraZeneca, and Pathos Partner to Build Oncology Foundation Model Using Multimodal Data

by Roman Kasianov   •   April 23, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI & Digital   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Tempus has announced new multi-year agreements with AstraZeneca and Pathos AI to co-develop what is described as the largest multimodal foundation model in oncology. 

The model will be trained on Tempus’ de-identified oncology datasets and is intended to support research across biological insight generation, target discovery, and therapeutic development. All three partners will have access to the resulting model for use in their respective R&D efforts. The deal includes $200 million in combined fees for data licensing and model development.

#advertisement
AI in Drug Discovery Report 2025

This builds on an existing partnership between Tempus and AstraZeneca dating back to 2021. The new phase reportedly aims to scale Tempus’ AI infrastructure and dataset repository to support broader therapeutic applications. According to Tempus CEO Eric Lefkofsky, the company’s long-term investment in data collection has laid the groundwork for applying generative AI in precision oncology at scale:

“Tempus has spent the last decade investing billions of dollars into collecting the necessary data needed for a foundation model of this kind to take shape..."

From AstraZeneca’s side, the collaboration is a part of its ongoing effort to integrate AI into its oncology R&D pipeline. Jorge Reis-Filho, Chief AI and Data Scientist for Oncology R&D at the company, framed the work as a way to improve the efficiency and success rate of drug development through large-scale data analysis.

Pathos is also contributing to the effort. The company, which recently began clinical testing of its CBP/p300 inhibitor pocenbrodib in metastatic prostate cancer, has been focused on integrating AI into trial design and patient selection. Pathos echoed a now-familiar view that foundation models, once considered speculative in biomedicine, are becoming technically viable.

The model is not yet built, and specifics on architecture, modality integration, or planned release timelines are yet to be disclosed.

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.